▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #749 by analyst upside · 2026-06-27
PRTA
Prothena Corporation plc
Healthcare · Market Cap $525M · P/E 0x
ANALYST PRICE TARGET
+113.6%
implied upside to consensus target
Current Price $10.02
Consensus Target $21.4
Bull Target $36.0
Bear Target $8.0
Analysts Covering 5
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
1
Hold
2
Sell
0
52-Week Low $5.96
52-Week High $11.8
YTD Return +8.9%
FUNDAMENTALS
Market Cap $525M
P/E Ratio (TTM) N/A
Forward P/E -7.6x
EPS (TTM) $-3.04
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $58M
Profit Margin -260.9%
52-WEEK RANGE
52-Week Low $5.96
52-Week High $11.8
Current Price $10.02
Bear Target $8.0
Bull Target $36.0
● Now $10.02 ● Target $21.4
TRADING DATA
Avg Volume 517K
YTD Return +8.9%
Analyst Count 5
Consensus Buy
Upside to Target +113.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Prothena Corporation plc (PRTA) is currently trading at $10.02 with a Wall Street consensus price target of $21.4, implying potential upside of 113.6% over the next 12 months. 5 analysts currently cover PRTA, with a consensus rating of Buy — 60% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $36.0, while the most cautious has a target of $8.0.

PRTA operates in the Healthcare sector with a market capitalisation of $525M. The stock is up 8.9% year-to-date and is currently trading near the upper end of its 52-week range of $5.96 – $11.8.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CRMD +93.6%
CorMedix Inc.
$616M · P/E 3.6x · Buy
ZVRA +106.3%
Zevra Therapeutics, Inc.
$799M · P/E 6.6x · Buy
KMDA +79.1%
Kamada Ltd.
$419M · P/E 20.7x · Buy
MDXG +65.4%
MiMedx Group, Inc.
$585M · P/E 19.6x · Buy
BVS +51.3%
Bioventus Inc.
$663M · P/E 23.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for PRTA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens — Reiterated
Market Outperform → Market Outperform 2026-05-08 Building track record
RBC Capital — Reiterated
Sector Perform → Sector Perform 2026-02-20 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2025-12-01 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-11-07 31% win rate (48 calls)
RBC Capital — Reiterated
Sector Perform → Sector Perform 2025-11-07 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2025-10-28 14% win rate (7 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-10-07 31% win rate (48 calls)
JMP Securities — Reiterated
Market Outperform → Market Outperform 2025-09-02 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →